A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

This trial is testing a drug called inavolisib in men with advanced prostate cancer that has stopped responding to hormone therapy (called metastatic castration-resistant prostate cancer, or mCRPC). **You may be eligible if...** - You have confirmed prostate cancer that has spread and stopped responding to hormone-lowering therapy - Your cancer is progressing based on rising PSA levels, new bone lesions on a scan, or measurable tumor growth - You have received at least one but no more than two prior hormonal therapies (ARPI) - Your overall health and organ function are adequate **You may NOT be eligible if...** - Your prostate cancer has neuroendocrine or small-cell features - You have received more than two prior hormonal therapies - You have untreated brain metastases or other serious conditions - Your organ function does not meet the study's minimum requirements Talk to your doctor to see if this trial is right for you.